Tessellate BIO
Diede Brunen has extensive experience in the biotechnology and pharmaceutical sectors, currently serving as Principal at BGV (BioGeneration Ventures) since November 2017, where previous roles included Senior Associate, Associate, and Analyst. Diede is also involved in various board observer positions for several companies, including ARTICA Therapeutics, Dunad Therapeutics, TigaTx Inc., Tessellate BIO, Genase Therapeutics, and Avidicure. Diede's academic background includes a PhD in Molecular Carcinogenesis and a Master of Science in Biomedical Sciences from Utrecht University, complemented by a Bachelor of Science in Biomedical Sciences. Early research experience includes a PhD candidacy at NKI-AVL and a research internship at The Hospital for Sick Children focused on autophagy in Listeria infection.
This person is not in the org chart
This person is not in any teams
Tessellate BIO
Tessellate BIO discovers and develops novel precision oncology medicines with the mission to turn cancer patients into cancer survivors. A private preclinical stage biotechnology company, Tessellate BIO is redefining Synthetic Lethality by developing drugs that target unexplored or difficult to drug pathways beyond HRD. Headquartered in the Netherlands and with research labs at the Stevenage Bioscience Catalyst, UK, Tessellate BIO is supported by top-tier life science investors BioGeneration Ventures (BGV) and Forbion.